DE69233773D1 - Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs - Google Patents

Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs

Info

Publication number
DE69233773D1
DE69233773D1 DE69233773T DE69233773T DE69233773D1 DE 69233773 D1 DE69233773 D1 DE 69233773D1 DE 69233773 T DE69233773 T DE 69233773T DE 69233773 T DE69233773 T DE 69233773T DE 69233773 D1 DE69233773 D1 DE 69233773D1
Authority
DE
Germany
Prior art keywords
topotecan
treatment
pharmaceutical composition
human
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233773T
Other languages
English (en)
Inventor
Randall Keith Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE69233773D1 publication Critical patent/DE69233773D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
DE69233773T 1991-02-21 1992-02-07 Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs Expired - Lifetime DE69233773D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65894891A 1991-02-21 1991-02-21
PCT/US1992/001028 WO1992014469A1 (en) 1991-02-21 1992-02-07 Treatment of ovarian cancer

Publications (1)

Publication Number Publication Date
DE69233773D1 true DE69233773D1 (de) 2009-11-19

Family

ID=24643386

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69233793T Expired - Lifetime DE69233793D1 (de) 1991-02-21 1992-02-07 Pharmazeutische Zusammensetzung zur Verwendung in der Behandlung von Eierstockkrebs
DE69233773T Expired - Lifetime DE69233773D1 (de) 1991-02-21 1992-02-07 Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69233793T Expired - Lifetime DE69233793D1 (de) 1991-02-21 1992-02-07 Pharmazeutische Zusammensetzung zur Verwendung in der Behandlung von Eierstockkrebs

Country Status (13)

Country Link
EP (3) EP1690542A3 (de)
JP (1) JP2778632B2 (de)
KR (1) KR930702983A (de)
AT (2) ATE444755T1 (de)
AU (1) AU663312B2 (de)
CA (1) CA2103708C (de)
DE (2) DE69233793D1 (de)
DK (2) DK0572557T3 (de)
ES (2) ES2334178T3 (de)
HK (1) HK1012265A1 (de)
MX (1) MX9200754A (de)
PT (1) PT100156B (de)
WO (1) WO1992014469A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101255406B (zh) * 2005-04-22 2010-05-26 李红霞 人卵巢癌耐药细胞株
ES2371171B1 (es) * 2010-06-08 2012-11-16 Consejo Superior De Investigaciones Científicas (Csic) Derivados de camptotecina como agentes antitumorales.
CN102477042A (zh) * 2010-11-26 2012-05-30 复旦大学 10-羟基喜树碱衍生物及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells

Also Published As

Publication number Publication date
EP1707568B1 (de) 2010-08-04
JP2778632B2 (ja) 1998-07-23
EP1707568A3 (de) 2008-03-26
ES2349037T3 (es) 2010-12-22
PT100156B (pt) 1999-09-30
AU1461692A (en) 1992-09-15
EP0572557A4 (en) 1993-12-29
MX9200754A (es) 1992-08-01
EP1690542A3 (de) 2008-03-26
DK0572557T3 (da) 2010-02-01
CA2103708A1 (en) 1992-08-22
AU663312B2 (en) 1995-10-05
ATE444755T1 (de) 2009-10-15
EP0572557B1 (de) 2009-10-07
DE69233793D1 (de) 2010-09-16
CA2103708C (en) 2004-04-27
JPH06505740A (ja) 1994-06-30
EP1690542A2 (de) 2006-08-16
KR930702983A (ko) 1993-11-29
PT100156A (pt) 1993-05-31
HK1012265A1 (en) 1999-07-30
WO1992014469A1 (en) 1992-09-03
EP0572557A1 (de) 1993-12-08
DK1707568T3 (da) 2010-11-08
ES2334178T3 (es) 2010-03-05
EP1707568A2 (de) 2006-10-04
ATE476182T1 (de) 2010-08-15

Similar Documents

Publication Publication Date Title
DE69233169D1 (de) Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.
DE69213814T2 (de) Melatoninderivate zur Behandlung von Schlafstörungen und zur Pre-Anästhesie
ATE152910T1 (de) Verwendung von taxol zur herstellung eines arzneimittels zur behandlung von krebs
NO890259L (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
DE69233773D1 (de) Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs
GR3015413T3 (en) Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases.
ATE280584T1 (de) Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe
EP1250926A3 (de) Die Verwendung von wasserunlöslichem S-Camptothecin mit geschlossenem Lactonring für die Herstellung eines Medikamentes zur Behandlung von Darmkrebs
HUT60145A (en) Process for producing pharmaceutical composition comprising human interleukin-2 and suitable for treating pneumothorax
ATE122889T1 (de) Verwendung von mizoribin zur behandlung oder vorbeugung der multiplen sklerose.
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients
HUT54300A (en) Process for producing medicaments suitable for antiviral treatment

Legal Events

Date Code Title Description
8364 No opposition during term of opposition